Tuberculosis (TB) is an infectious disease caused by members of the Mycobacterium tuberculosis complex (MTBC). TB primarily affects the lungs, yet it also spreads to other parts of the body. Health of afflicted patients degrades gradually, eventually leading to death if left untreated.

TB is one of the top 10 causes of death worldwide. It is also the main killer related to antimicrobial resistance and among carriers of HIV. Up to 10 million people are infected globally with tuberculosis. A staggering 1.7 million died of it in 2014¹. 

Tuberculosis is curable when the right antibiotic therapy is given to the patient. With resistance now prevalent, the key is early and precise diagnosis of the disease. Gold standard for TB diagnosis is culture but this is very slow. Diagnosis based solely on culture therefore delays the correct therapy for weeks, thus endangering the patient as well as increasing the risk of spreading antibiotic resistant forms of TB.

Current practices have led to the rise of even more deadly forms of the infections known as MDR-TB, XDR-TB and TDR-TB². These multi-resistant strains require quick identification, otherwise their presence will increase ever-more.

At Clemedi we are developing a diagnostic solution that identifies disease-causing Mycobacteria and predicts antibiotic susceptibility to several antibiotics – all of this within 24 hours!

Our new products, thus save lives and prevents further spread of mycobacterial resistance.